Marina N Nikiforova1, Yuri E Nikiforov. 1. Department of Pathology and Laboratory Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND: The accuracy of cancer detection in thyroid nodules by fine-needle aspiration (FNA) cytology and prognostication of thyroid cancer needs further improvement and can benefit from testing for molecular alterations known to occur in thyroid tumors. SUMMARY: Recent studies have demonstrated the feasibility of mutation detection in clinical FNA samples from thyroid nodules and their contribution to improving the diagnostic accuracy of FNA cytology. It appears that molecular testing is most beneficial for thyroid FNA samples with indeterminate cytology, where it can resolve the diagnosis in a significant number of cases. In addition to BRAF mutation, which has been studied most extensively, detection of RAS, RET/PTC, and PAX8/PPARgamma mutations also contribute substantially to cancer diagnosis. Some of these molecular markers, particularly BRAF, can also be used for tumor prognostication. In clinical setting, molecular testing of thyroid FNA samples and surgically removed tumors should utilize a restricted number of techniques that provide high accuracy and specificity of mutation detection. CONCLUSION: Testing for cancer-specific mutations in thyroid FNA samples and surgically removed tumor tissues increases diagnostic accuracy of FNA cytology and offers better prognostication of thyroid cancer.
BACKGROUND: The accuracy of cancer detection in thyroid nodules by fine-needle aspiration (FNA) cytology and prognostication of thyroid cancer needs further improvement and can benefit from testing for molecular alterations known to occur in thyroid tumors. SUMMARY: Recent studies have demonstrated the feasibility of mutation detection in clinical FNA samples from thyroid nodules and their contribution to improving the diagnostic accuracy of FNA cytology. It appears that molecular testing is most beneficial for thyroid FNA samples with indeterminate cytology, where it can resolve the diagnosis in a significant number of cases. In addition to BRAF mutation, which has been studied most extensively, detection of RAS, RET/PTC, and PAX8/PPARgamma mutations also contribute substantially to cancer diagnosis. Some of these molecular markers, particularly BRAF, can also be used for tumor prognostication. In clinical setting, molecular testing of thyroid FNA samples and surgically removed tumors should utilize a restricted number of techniques that provide high accuracy and specificity of mutation detection. CONCLUSION: Testing for cancer-specific mutations in thyroid FNA samples and surgically removed tumor tissues increases diagnostic accuracy of FNA cytology and offers better prognostication of thyroid cancer.
Authors: John R Jalas; Swapna Vemula; Vladimir Bezrookove; Philip E Leboit; Jeffry P Simko; Boris C Bastian Journal: Am J Surg Pathol Date: 2011-09 Impact factor: 6.394
Authors: Anil K D'Cruz; Richa Vaish; Abhishek Vaidya; Iain J Nixon; Michelle D Williams; Vincent Vander Poorten; Fernando López; Peter Angelos; Ashok R Shaha; Avi Khafif; Alena Skalova; Alessandra Rinaldo; Jennifer L Hunt; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2018-04-06 Impact factor: 2.503
Authors: Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman Journal: Endocr Rev Date: 2011-08-31 Impact factor: 19.871
Authors: Yuri E Nikiforov; N Paul Ohori; Steven P Hodak; Sally E Carty; Shane O LeBeau; Robert L Ferris; Linwah Yip; Raja R Seethala; Mitchell E Tublin; Michael T Stang; Christopher Coyne; Jonas T Johnson; Andrew F Stewart; Marina N Nikiforova Journal: J Clin Endocrinol Metab Date: 2011-08-31 Impact factor: 5.958